CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS

OBJECTIVE: To validate sphingomyelin (SM) dosage in the cerebrospinal fluid (CSF) of patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and Guillain-Barré syndrome (GBS) as a reliably assessable biomarker. METHODS: We prospectively enrolled 184 patients from six It...

Descripción completa

Detalles Bibliográficos
Autores principales: Capodivento, Giovanna, De Michelis, Chiara, Carpo, Marinella, Fancellu, Roberto, Schirinzi, Erika, Severi, Daniele, Visigalli, Davide, Franciotta, Diego, Manganelli, Fiore, Siciliano, Gabriele, Beronio, Alessandro, Capello, Elisabetta, Lanteri, Paola, Nobile-Orazio, Eduardo, Schenone, Angelo, Benedetti, Luana, Nobbio, Lucilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Neuromuscular
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892388/
https://www.ncbi.nlm.nih.gov/pubmed/33093191
http://dx.doi.org/10.1136/jnnp-2020-324445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892388/
https://www.ncbi.nlm.nih.gov/pubmed/33093191
http://dx.doi.org/10.1136/jnnp-2020-324445

Ejemplares similares